Perspectives for pharmaceutical screening at XFEL sources using the example of Lassa virus endonuclease

Falke, S.; Reinke, P.Y.A.; Rosenberg, D.; Fischer, P.; Meyer, J.; Galchenkova, M.; Tolstikova, A.; Mariani, V.; Senst, J.M.; Lewe, P.; Witt, S.; Wagner, A.; Chapman, H.N.; Hunter, M.; Günther, S.; Meents, A.

doi:10.1107/S2059798326009435

Figure 2
(a) LASVendo crystals used for data collection. (b) Cartoon representation of LASVendoN apo protein as solved by SFX. The inset shows the Mg²⁺ binding at the active site with distances shown in Å. (c) Structure and active-site interactions of 2,4-dioxo-4-phenylbutanoic acid (DPBA) and (d) baloxavir acid (BXA). The common diketo carboxylic acid scaffold is coloured red. (e) Superposition of the LASVendoN apo protein (orange), LASVendoN in complex with DPBA (light blue) and with BXA (green). Main-chain r.m.s.d. values of the protein–ligand complexes superimposed with the apo protein are below 1 Å.

STRUCTURAL
BIOLOGY

ISSN: 2059-7983

Volume 82| Part 10| October 2026| Pages 1181-1194

https://doi.org/10.1107/S2059798326009435

Open

access